Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Celecoxib
Drug ID BADD_D00410
Description Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.[A34124]
Indications and Usage For relief and management of osteoarthritis (OA), rheumatoid arthritis (RA), juvenile rheumatoid arthritis (JRA), ankylosing spondylitis, acute pain, primary dysmenorrhea and oral adjunct to usual care for patients with familial adenomatous polyposis
Marketing Status Prescription
ATC Code L01XX33; M01AH01
DrugBank ID DB00482
KEGG ID D00567
MeSH ID D000068579
PubChem ID 2662
TTD Drug ID D03RTS
NDC Product Code 70247-006; 42806-720; 43063-967; 72567-001; 16714-731; 59385-055; 67296-1600; 51079-199; 65162-819; 50436-0144; 46708-268; 68788-7735; 80425-0167; 65862-793; 13668-307; 69097-422; 80425-0096; 12598-9531; 69097-423; 12598-9516; 55111-898; 67296-1399; 71335-0868; 60429-460; 71610-283; 57582-032; 61919-360; 29300-373; 68180-398; 0591-3984; 70934-220; 0591-3983; 55289-451; 42571-142; 59762-1518; 51655-253; 68180-399; 62332-140; 60687-436; 57582-213; 68788-7286; 64552-4032; 53104-7533; 42806-722; 76420-009; 71209-056; 70518-1346; 65977-0052; 72189-123; 70934-213; 62704-0046; 59746-563; 77771-157; 0378-7150; 0025-1515; 71205-027; 42571-143; 70518-2748; 80425-0040; 75834-236; 65862-908; 71209-054; 63187-301; 42571-144; 63629-8156; 51927-5063; 55700-613; 13668-441; 53002-1338; 0025-1520; 50090-5178; 69367-302; 60687-447; 75834-237; 55154-7646; 50090-3183; 59762-1515; 0093-7165; 80425-0142; 43063-669; 42806-721; 62332-143; 55154-7645; 0591-3985; 68788-7264; 60505-3847; 60505-3849; 0378-7160; 55700-607; 70518-3204; 60505-3848; 71335-0936; 59762-1516; 69097-420; 0093-7170; 45865-970; 63187-633; 70934-469; 61919-837; 51079-215; 69117-0020; 65862-909; 0615-8338; 50228-156; 75834-239; 68981-025; 68180-396; 68071-4476; 69680-135; 69367-301; 65162-820; 0904-6503; 0378-7170; 52048-1995; 29300-157; 16714-734; 50268-168; 77771-156; 33342-158; 77777-115; 50228-159; 0378-7165; 70247-009; 70247-007; 69117-0021; 50090-5638; 42571-145; 69117-0022; 0093-7166; 70934-026; 51552-1461; 80425-0038; 60760-823; 43063-825; 57582-212; 72969-008; 71209-055; 53002-2338; 13668-310; 42708-016; 71205-020; 80425-0039; 67296-1608; 59746-561; 71610-584; 77771-159; 47621-024; 63187-643; 71335-0292; 0025-1530; 65162-818; 77771-158; 65862-910; 80425-0037; 67296-1345; 75834-238; 63187-562; 71335-2019; 71205-439; 71205-055; 65427-002; 60429-462; 13668-442; 62332-141; 62512-0018; 29300-158; 33342-156; 0025-1525; 68071-4392; 58159-067; 46708-267; 72241-025; 60429-461; 46708-270; 68071-4642; 70518-3292; 59762-1517; 65691-0048; 55289-475; 0904-6502; 50228-157; 57582-214; 61919-043; 69097-421; 71335-1804; 72241-023; 62332-142; 43353-257; 60760-824; 63187-079; 29300-374; 16714-733; 0591-3982; 50228-158; 43744-071; 50090-4789; 71209-057; 46708-838; 33342-155; 16714-732; 59746-564; 49706-1880; 63629-3021; 50268-169; 45865-943; 65162-817; 66651-919; 69117-0023; 72761-022; 71335-1066; 68180-395; 68724-1004; 68071-2626; 70518-2922; 65015-882; 57582-211; 33342-157; 72241-022; 45865-840; 46708-269; 65862-907; 42806-723; 59746-562; 60760-209; 0093-7306; 54245-3392; 70247-008; 61919-682; 60429-459; 72241-024
Synonyms Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Celebrex | SC 58635 | SC-58635 | SC58635
Chemical Information
Molecular Formula C17H14F3N3O2S
CAS Registry Number 169590-42-5
SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood glucose increased13.02.02.002--Not Available
Blood potassium decreased13.11.01.010--Not Available
Blood potassium increased13.11.01.0110.000459%Not Available
Blood pressure abnormal13.14.03.0010.000345%Not Available
Blood pressure decreased13.14.03.002--Not Available
Blood pressure increased13.14.03.0050.002182%Not Available
Blood pressure systolic increased13.14.03.0060.000345%Not Available
Blood sodium increased13.11.01.013--Not Available
Blood testosterone decreased13.10.05.004--Not Available
Blood triglycerides increased13.12.03.001--Not Available
Blood urea increased13.13.01.0060.000689%Not Available
Blood uric acid increased13.02.04.001--Not Available
Blood urine13.13.02.011--Not Available
Body temperature increased13.15.01.0010.000230%Not Available
Bone disorder15.02.04.0040.000574%Not Available
Breast cancer16.10.01.001; 21.05.01.003--Not Available
Breast neoplasm21.05.01.004; 16.10.02.001--Not Available
Breast pain21.05.05.0030.000230%
Breast tenderness21.05.05.004--Not Available
Bronchitis22.07.01.001; 11.01.09.001--
Bronchospasm10.01.03.012; 22.03.01.0040.000345%
Bundle branch block left02.03.01.0070.000345%Not Available
Bundle branch block right02.03.01.0110.000230%Not Available
Burning sensation17.02.06.001; 08.01.09.0290.001034%Not Available
C-reactive protein increased13.09.01.0070.000919%Not Available
Cardiac arrest02.03.04.0010.000539%
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002--Not Available
Cardiomegaly02.04.02.0010.000090%Not Available
Cardiomyopathy02.04.01.001--Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 24 Pages